Target intelligence / Profile preview

Ketosis induction via carbohydrate limitation

Molecular classification
Other
01

Overview

Ketosis induction via carbohydrate limitation refers to the metabolic process by which restricting dietary carbohydrates—typically to less than 50 grams per day—leads to depletion of glycogen stores and triggers the liver to produce ketone bodies from fatty acids through β‑oxidation. This shift provides an alternative energy source for organs such as the brain when glucose availability is low. The resulting state of elevated blood ketones is called nutritional or dietary ketosis. This process underlies several therapeutic diets including the ketogenic diet and its variants (very-low-carbohydrate KD, medium-chain-triglyceride KD). While not itself a druggable molecular target like an enzyme or receptor, this metabolic pathway has significant clinical relevance for weight loss, glycemic control in type 2 diabetes mellitus, epilepsy treatment, and potentially other chronic conditions such as neurodegenerative diseases and cardiometabolic disorders. Safety concerns include transient side effects during adaptation (“keto flu”) and possible increases in LDL-cholesterol among certain individuals.

Other names
Ketosis inductionCarbohydrate restriction-induced ketosisNutritional ketosis via carbohydrate limitationDietary ketosis
02

Mechanism of action

Not applicable; this is a physiological process rather than a discrete molecular target.

03

Biological functions

Energy metabolismFat oxidationKetone body production (ketogenesis)Glucose sparing for the brain and other tissues
04

Disease associations

Obesity managementType 2 diabetes managementEpilepsy (as part of ketogenic diet therapy)Potential roles in neurodegenerative diseases, polycystic kidney disease, and cardiometabolic health
05

Safety considerations

Initial side effects during keto-induction phase ("keto flu"): constipation, halitosis, muscle spasms, diarrhea, skin rash; typically resolve within weeksPotential elevations in LDL-cholesterol in some individuals ("lean mass hyper-responder" phenotype), which may increase cardiovascular risk for certain populations
06

Interacting drugs

No direct drugs interact with "ketosis induction via carbohydrate limitation" as it is a metabolic state, not a molecular target. However, exogenous ketones or ketogenic precursors (e.g., medium-chain triglycerides) can be used to induce or augment ketosis
07

Biomarkers

Blood beta-hydroxybutyrate (BHB) levels (>0.5 mmol/L defines dietary ketosis)Urinary ketonesReduced blood glucose and insulin levels

Beyond the preview

Go deeper on Ketosis induction via carbohydrate limitation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ketosis induction via carbohydrate limitation.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call